SLC5A2 and hydrops fetalis: This network meta-analysis found that, for patients with HFpEF or HFmrEF, no included drug classes were significantly associated with a reduced risk of death, but SGLT2 inhibitors, ARNIs, and MRAs were associated with a significant decrease in the risk of HF admission; SGLT2 inhibitors were the optimal drug class.